Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.

Abstract: Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Abstract: Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Abstract: Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Abstract: Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Abstract: This application claims a method for detecting biologically active substances, comprising the following steps a) providing a support carrying substances to be tested b) providing a suspension containing luminescent microorganisms, c) coating the support with the suspension of microorganisms, d) detecting the biologically active substances on the support by detecting the change in luminescence of the suspension of microorganisms, and e) stimulating the luminescence of the microorganisms before or during detection, and/or f) extending the period of luminescence of the microorganisms by employing substances for regulating and extending the period of luminescence of the microorganisms.

Abstract: The invention provides compounds of the formula (I) in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

Abstract: This application claims a method for detecting biologically active substances, comprising the following steps a) providing a support carrying substances to be tested b) providing a suspension containing luminescent microorganisms, c) coating the support with the suspension of microorganisms, d) detecting the biologically active substances on the support by detecting the change in luminescence of the suspension of microorganisms, and e) stimulating the luminescence of the microorganisms before or during detection, and/or f) extending the period of luminescence of the microorganisms by employing substances for regulating and extending the period of luminescence of the microorganisms.

Abstract: The invention claimed herein is a kit for detecting biologically active substances on a support, comprising the luminescent marine bacteria Vibria Fischeri in a form stabilized for transport and storage, one or more cultivation media or the individual components of cultivation media for the microorganism wherein the cultivation media contains 100 mg/l to 500 mg/l of aspartic acid, and optionally additives for extending the period of luminescence selected from N-acylhomoserine lactones, dipeptides, oligopeptides, or their biochemical precursors, and boron compounds.

Abstract: The invention relates to a method for detecting biologically active substances, comprising the steps

Abstract: The present invention relates to novel optionally substituted 8-cyano-1-cyclo-propyl-7-(2,8-diazabicyclo[4.3.

Abstract: Intermediates useful in the preparation of 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl-6-fluorol,4-dihydro-4-oxo-3-quinolinecarboxylic acids of the following structures are claimed.

Abstract: The mixture to be tested for toxic components is first separated into fractions by chromatography. The separated fractions are then contacted with luminescent microorganisms in the chromatographic system itself and the toxicity of the fractions is determined by measurement of the bioluminescence. The chromatographic separation may be carried out either by thin layer chromatography or by column liquid chromatography.

Abstract: The invention concerns novel plant-treatment agents comprising: at least one thermoplastically processable biodegradable polyester amide, optionally in a mixture with one or a plurality of further thermoplastically processable, biodegradable polymer components; at least one agrochemical substance; and optionally additives. The invention further concerns a process for preparing these agents, and their use in the application of agrochemical substances.

Abstract: Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.